A Phase I Single Arm Open-Label Study of Erlotinib and 13-cis-Retinoic Acid (CRA) in Patients With Recurrent Malignant Glioma.
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Erlotinib (Primary) ; Isotretinoin (Primary)
- Indications Glioma
- Focus Adverse reactions; Biomarker
- 07 Jun 2017 Biomarkers information updated
- 30 Jan 2013 Planned end date changed from 1 Feb 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 30 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.